QT prolongation
Myocarditis
Agranulocytosis in 1%–2% of patients during initial treatment 3 months
Highest ~3 months into treatment and then decreases
Other potential side effects:
Dyslipidemia
Diabetes
Decreased seizure threshold
"Other adverse cardiovascular and respiratory effects" 
"Increased mortality in elderly patients with dementia-related psychosis"
Highest ~3 months into treatment and then decreases
Dyslipidemia
Diabetes
Decreased seizure threshold
Clozapine
Chlorpromazine
Ziprasidone
Aripiprazole
Risperidone
Olanzapine
Haloperidol
Methylphenidate